Jonathan Decarpentrie, PhD researcher at the university of Namur presented his...
Prof Marc van den Eynde, digestive oncologist at Cliniques Universitaires...
Dr Eline Naert, a medical oncologist at Ghent University Hospital interviews...
The TULIP trial represents a pivotal phase 3 study conducted to assess the...
During ESMO 2023 MediMIx had the honour to organise a discussion on...
At ESMO 2023, exciting data on lung cancer were presented, including insights...
Prof Jeroen Dekervel, gastrological oncologist at University Hospital Leuven...
The AdvanTIG-202 study represents an open-label phase 2 clinical trial...
In this discussion, Prof Jean-François Beaurain, a medical oncologist at...
During ESMO 2023 Prof Hurwitz, affiliated with the Fred Hutch Cancer Center in...